ADCETRIS (brentuximab vedotin) for injection

Adcetris is a brand-name prescription medication that’s used to treat certain forms of lymphoma in adults. Lymphoma is a form of cancer that affects your lymphatic system and certain white blood cells called lymphocytes. Specifically, Adcetris is FDA-approved to treat: Classical Hodgkin lymphoma (cHL).

Home | brentuximab vedotin for injection

ADCETRIS (brentuximab vedotin) for injection price in India and overseas
ADCETRIS (brentuximab vedotin) for injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ADCETRIS (brentuximab vedotin) for injection

Adcetris is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma.

ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of patients with:
• Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.
• Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

In the United States, brentuximab vedotin is indicated for the treatment of hodgkin lymphoma, systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides.

In the European Union, brentuximab vedotin is indicated for the treatment of hodgkin lymphoma, systemic anaplastic large cell lymphoma, and cutaneous T cell lymphoma.

Drug (Brand / Generic): ADCETRIS / brentuximab vedotin
Current Indication: treat or prevent relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL)
Approval Date: August 19, 2011

For injection: 50 mg lyophilized powder in a single-use vial.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.